The Science of Biosimilars And the Future of Interchangeability

Biological products differ from traditional small-molecule drugs (SMDs) in many ways that present unique considerations for their study, approval, and use.

Much progress has occurred in the approval and availability of biosimilars; however, some uncertainties remain. For example, the FDA recently released guidance for industry on demonstration of